$130 Million is the total value of Foresite Capital Management V, LLC's 14 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | $19,805,000 | +12.8% | 1,258,243 | 0.0% | 15.23% | +24.1% | |
| Theseus Pharmaceuticals, Inc. | $19,345,000 | +4.9% | 3,335,346 | 0.0% | 14.87% | +15.4% | ||
| HIMS | Hims & Hers Health, Inc. | $18,524,000 | +23.2% | 3,319,786 | 0.0% | 14.24% | +35.6% | |
| Pardes Biosciences Inc | $17,391,000 | -39.7% | 9,400,515 | 0.0% | 13.37% | -33.7% | ||
| KNTE | Kinnate Biopharma Inc. | $10,456,000 | -5.2% | 875,001 | 0.0% | 8.04% | +4.3% | |
| Somalogic, Inc. | $10,198,000 | -35.8% | 3,516,472 | 0.0% | 7.84% | -29.4% | ||
| CMPX | Compass Therapeutics, Inc. | $10,032,000 | -14.0% | 4,400,000 | 0.0% | 7.71% | -5.3% | |
| ACET | Adicet Bio, Inc. | $9,670,000 | -2.6% | 680,000 | 0.0% | 7.44% | +7.2% | |
| Invivyd, Inc. | $4,482,000 | -4.6% | 1,431,826 | 0.0% | 3.45% | +5.0% | ||
| GMTX | Gemini Therapeutics, Inc. | $3,994,000 | -2.9% | 2,435,125 | 0.0% | 3.07% | +6.8% | |
| QSI | Quantum-Si Incorporated | $2,542,000 | +18.5% | 924,379 | 0.0% | 1.96% | +30.4% | |
| ENTA | Enanta Pharmaceuticals, Inc. | $2,192,000 | +9.8% | 42,250 | 0.0% | 1.68% | +20.8% | |
| ME | 23andMe Holding Co. | $1,164,000 | +15.4% | 406,913 | 0.0% | 0.90% | +27.0% | |
| PHVS | Pharvaris N.V. | $262,000 | -65.3% | 34,142 | 0.0% | 0.20% | -61.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.